The University of Edinburgh
Translational and mechanistic studies of protection of human kidney cells from injury
Abstract
dc:description.abstractAcute kidney injury (AKI) is a common syndrome, affecting up to 14% of patients in hospital and with no specific treatment. It is associated with significant morbidity and mortality and affects patients under the care of all specialities. Patients who have cardiac surgery are particularly vulnerable to AKI in that they often have multiple risk factors for AKI such as older age, hypertension, and type II diabetes. Planned cardiac bypass surgery gives an opportunity to study ischaemia reperfusion injury (IRI) to the kidney, and allows the testing of potential protective agents and therefore translation from preclinical studies. The drug Heme Arginate (HA) has been in clinical use for more than 20 years for the treatment of acute porphyria and has a good safety profile. Interestingly, HA treatment induces upregulation of the anti-inflammatory enzyme heme oxygenase-1 (HO-1) and preclinical studies have indicated that HA protects aged mice from renal IRI with macrophage HO-1 expression being critical. Despite encouraging data from Phase I studies in healthy volunteers, HA has not been used in an elderly and comorbid patient population of patients with cardiac disease. There is a known association between iron and inflammation. Therefore, the Heme Arginate in patients planned for Cardiac Surgery (HACS) clinical trial was designed to investigate if HA effectively induces HO-1 expression and if it is safe in this patient group. The HACS trial demonstrated that HO-1 gene expression in peripheral blood mononuclear cells was significantly increased, but that HO-1 protein was not upregulated. There was however a significant increase in HO-1 protein in serum. A recent study of HO-1 expression in the human heart following HA dosing has provided comparable results for peripheral blood mononuclear cells in a similar aged and comorbid patient group. Results will inform future Phase II and Phase III clinical trials. Continuing the theme of repurposing drugs licensed for human use, dimethyl fumarate (DMF) is a fumaric acid ester which is licensed for the treatment of multiple sclerosis (MS) and psoriasis. Its exact mechanisms of action are unknown but likely involves activation of the strongly anti-inflammatory nuclear factor erythroid 2–related factor 2 (Nrf2) pathway (of which HO-1 is downstream) and inhibition of the nuclear localisation of the transcription factor NF-B. Preclinical studies have suggested that macrophages are key to both the development of AKI and subsequent kidney repair. A treatment which could alter macrophage phenotype from pro-inflammatory (classically activated/M1) to anti-inflammatory reparative (alternatively activated/M2) would be of interest in AKI. Experimental work in vitro and in vivo was carried out to examine the effect of DMF on the Nrf2 pathway and to explore the effect of DMF on both murine and human macrophages. Interestingly, DMF reduced phagocytosis of apoptotic cells by murine bone marrow derived macrophages (BMDMs) at high dose, but pilot data suggested that DMF treatment ameliorated the classically activated M1 phenotype of BMDMs as measured by nitrite production. In addition, DMF administration to mice upregulated Nrf2 dependent genes including HO-1 in kidney tissue. Preliminary studies of the effect of DMF upon murine renal IRI did not show protection from AKI although the severity if the injury may have precluded this and further work is required. It is hoped that HA may offer therapeutic potential in the prevention and treatment of IRI and further clinical trials are ongoing. DMF offers potential as an attractive oral anti-inflammatory therapy and merits further study.
Degree
thesis:*- Grantor dc:publisher
- The University of Edinburgh
- Year dc:date.issued
- 2023
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Duthie, Fiona Anne Ingrid
- Advisors dc:contributor.advisor
-
- Hughes, Jeremy
- Kluth, David
Subjects
dc:subject × 7Rights
- Language dc:language.iso
- en
Identifiers
dc:identifier.*- Identifier URI
- http://dx.doi.org/10.7488/era/3880